Mark Konijnenberg

Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate and breast cancers and hence serves as a legitimate target for radionuclide therapy (TRT). Radiolabeled GRPR antagonists are attractive radionuclide-carriers for TRT, due to their rapid tissue penetrati...